Does HIV Influence Hepatitis C Cure Rates Using Direct-Acting Antivirals?

Area of Science:

• Hepatology
• Infectious Diseases
• Virology

Background:

• Hepatitis C virus (HCV) coinfection affects approximately one-third of individuals living with human immunodeficiency virus (HIV).
• HCV/HIV coinfection is associated with accelerated liver disease progression and poorer treatment responses to traditional interferon-based therapies.
• Previous antiviral treatments for HCV showed reduced efficacy in coinfected patients.

Purpose of the Study:

• To evaluate the efficacy of novel interferon-free direct-acting antiviral (DAA) regimens in patients coinfected with HIV and HCV.
• To determine if the treatment response disparities observed with older therapies persist with modern DAA regimens.

Main Methods:

• Review of recent clinical studies and real-world data comparing DAA treatment outcomes in HCV/HIV coinfected individuals versus HCV mono-infected individuals.
• Analysis of sustained virologic response (SVR) rates across different DAA regimens.

Main Results:

• Emerging evidence suggests that interferon-free DAA regimens achieve comparable SVR rates in HCV/HIV coinfected patients to those in HCV mono-infected patients.
• The disparity in treatment response previously seen with interferon-based therapies does not appear to extend to DAA regimens.

Conclusions:

• Direct-acting antiviral (DAA) therapy represents a significant advancement for treating hepatitis C virus (HCV) in coinfected HIV patients.
• HCV/HIV coinfected individuals can now expect similar successful treatment outcomes with modern DAA regimens as those with HCV mono-infection.